Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.

Eliasson L, Clifford S, Barber N, Marin D.

Leuk Res. 2011 May;35(5):626-30. doi: 10.1016/j.leukres.2010.10.017. Epub 2010 Nov 20.

PMID:
21095002
2.

Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J.

Pharmacoeconomics. 2007;25(6):481-96.

PMID:
17523753
3.

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.

Chen LC, Chen TC, Huang YB, Chang CS.

Int J Clin Pharm. 2014 Feb;36(1):120-7. doi: 10.1007/s11096-013-9867-8. Epub 2013 Oct 24.

4.

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ.

Blood. 2002 May 15;99(10):3530-9.

5.

Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.

Wu S, Chee D, Ugalde A, Butow P, Seymour J, Schofield P.

Palliat Support Care. 2015 Apr;13(2):255-63. doi: 10.1017/S1478951513001260. Epub 2014 Feb 13.

PMID:
24524212
6.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
7.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
8.

Current status of imatinib as frontline therapy for chronic myeloid leukemia.

Marin D.

Semin Hematol. 2010 Oct;47(4):312-8. doi: 10.1053/j.seminhematol.2010.06.003. Review.

PMID:
20875547
9.

[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].

Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.

Ai Zheng. 2004 Dec;23(12):1696-9. Chinese.

PMID:
15601563
10.

Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan.

Chen TC, Chen LC, Huang YB, Chang CS.

Int J Clin Pharm. 2014 Feb;36(1):172-81. doi: 10.1007/s11096-013-9876-7. Epub 2013 Nov 19.

11.

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R.

Clin Cancer Res. 2002 May;8(5):935-42.

12.

Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.

Tóthová E, Kafková A, Fricová M, Benová B, Kirschnerová G, Tóthová A.

Neoplasma. 2005;52(1):63-7.

PMID:
15739029
13.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP; International Randomised Study of Interferon versus STI571 (IRIS) Study Group.

N Engl J Med. 2003 Oct 9;349(15):1423-32.

14.

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Roche-Lestienne C, Darré S, Laï JL, Facon T, Guilhot J, Preudhomme C.

Haematologica. 2005 Jan;90(1):131-3.

15.

[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].

Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):1-5. Chinese.

PMID:
15946498
16.

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia.

Clin Cancer Res. 2006 May 15;12(10):3037-42.

17.

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.

Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H.

Cancer. 2003 Sep 15;98(6):1105-13.

18.

Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.

Daouphars M, Ouvry M, Lenain P, Rouvet J, Jardin F, Bubenheim M, Varin R.

Pharmacotherapy. 2013 Feb;33(2):152-6. doi: 10.1002/phar.1174. Epub 2013 Jan 28.

PMID:
23359430
19.

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

Breccia M, Efficace F, Alimena G.

Cancer Lett. 2011 Jan 28;300(2):115-21. doi: 10.1016/j.canlet.2010.10.018. Epub 2010 Nov 12. Review.

PMID:
21074936
20.

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.

Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.

Ann Hematol. 2006 Dec;85(12):841-7. Epub 2006 Sep 28.

PMID:
17006667

Supplemental Content

Support Center